Head-to-head evidence
NBI-1117568 vs NTX-253
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Muscarinic M4 receptor · full Schizophrenia pipeline
NBI-1117568
Developed by Neurocrine Biosciences under a licence from Nxera Pharma
NCT05545111 · Phase 2 · completed
The study randomly assigned 210 participants to four NBI-1117568 dose groups or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2027 · NCT06963034 (registry estimate)
NTX-253
Developed by Neurosterix Pharma Sàrl
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NBI-1117568's landscape · NTX-253's landscape